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1  Introduction 
1.1  Glioblastoma 
In 1858 Rudolf Virchow described glia cells for the first time in medical history [1]. 
Seven years later he pathologically characterized gliomas, separating them into low- 
and high-grade glioma [2].  
1.1.1 Taxonomy, epidemiology and general features of GBM 
Today, Glioblastoma (GBM) terms a tumor entity of the central nervous system 
(CNS) that arises from normal brain parenchyma and is classified as WHO grade IV. 
Therefore it belongs, next to Gliosarcoma, Pineoblastoma or all embryonal tumors 
of the central nervous system (CNS), to the subgroup of the most malignant CNS 
tumors which are normally associated with poor prognosis [3]. On cellular basis, it is 
characterized by a high level of mitotic activity, endothelial proliferation, necrotic 
areas and wide ranged invasion of adjacent brain parenchyma. Patients, if not 
asymptomatic, suffer from typical symptoms of raised intracranial pressure, like 
(tension) headache, nausea and vomiting, as well as focal neurological deficits, e.g. 
epileptic episodes, seizure or personality changes [3, 4]. 
According to the Central Brain Tumor Registry of the United States (CBTRUS; 
presenting data collected between 2010 and 2014), GBM had an incidence rate of 
3.2 per 100,000 population in the US [5]. According to the report of Ostrom et al., it 
accounted for 14.9% of all primary brain and other CNS tumors and 47.1% of 
primary malignant brain tumors. It was 1.58 times more common in male than in 
female patients and was diagnosed at a median age of 64 years. Despite all 
treatment efforts, Glioblastoma comes with a poor prognosis of an estimated 5.5% 
survival rate 5 years post diagnosis [6]. Here, highly infiltrative and migratory 
behavior of GBM cells within the brain are considered as important factors for short 
survival rates and will be discussed further down. On the other hand, formation of 
extra-CNS metastasis of GBM (ECMGBM) is a rarely seen phenomenon in GBM 
patients and has been found in the lungs, lymphatic nodes, liver, bones or the 
pancreas [7]. Ogungbo et al. also reported a case in which a metastasis had been 
found in the patient’s parotid gland [8]. In a study performed by Müller et al. [9], 
GFAP positive circulating tumor cells were found in the peripheral blood from 29 of 
141 (20.6%) GBM patients. 
3 
 
1.1.2 GBM subtypes and molecular diagnostic 
To understand the nature of GBM and to individualize treatment for a better 
outcome, a major task is to distinguish between its subtypes. A general difference is 
made between primary and secondary GBM. Primary GBM arise de novo, are 
commonly diagnosed in patients older than 50 years and show a small-cell type; in 
contrast, secondary glioblastoma are the terminus of the malignant transformation 
originating from astrocytoma and occur more frequently in younger to middle-aged 
patients and present a giant-cell type phenotype [4, 10, 11]. Additionally, 5% of 
glioblastoma cases are associated with family history, mostly without detectable 
genetic cause and rarely due to genetic syndromes, e.g. Li-Fraumeni-syndrome, 
Turcot's syndrome or neurofibromatosis types 1 and 2 [4].  
On the other hand, Kleihues and Oghaki suggested already twenty years ago to 
supplement clinical and histologic features by genetic data to separate primary from 
secondary GBM [12]. Up today, classification on a molecular level is a well-
established method [13, 14], because diagnostic, prognostic or predictive 
information is available [15, 16]. The impact of molecular markers went so far that 
whole therapy algorithm, i.e. whether temozolomide should be applied or not, are 
based on different expression patterns. The important role of molecular markers 
finally found its representation within the actual WHO classification of CNS tumors 
[3]. For GBM, the isoenzymes of isocitrate dehydrogenase (IDH1 and IDH2) and the 
methylation of the O6-methylguanin-DNA methyltransferase (MGMT) promoter are 
the most important markers and hence were integrated into neuropathological 
routine assessment guidelines for glioma diagnostics [13]. A third well established 
molecular marker is loss of heterozygosity of 1p and 19q, the molecular signature of 
oligodendroglial tumours which provides prognostic value for those entities [15].  
Five genes encode three isoforms of IDH, but only IDH1 and 2 are known to play a 
role for cancer research [14]. Being either located in the cytosol and peroxisomes 
(IDH1) or in mitochondria (IDH2) [14], these enzymes physiologically catalyze the 
oxidative decarboxylation of isocitrate to α-ketoglutarate and carbon dioxide with 
reduction of the cofactor nicotinamide adenine dinucleotide phosphate (NADP+) 
[13]. Point mutations in codon 132 of the IDH1 gene (over 85-90% of detected 
alterations [13, 15] or in codon 172 of the IDH2 gene (only around 3% of the cases 
[15]) appear to occur at an early stage of glioma transformation and are more 
frequents in younger patients [14]. As demonstrated by a meta-analysis published 
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by Cheng et al., including over 1600 patients with glioblastoma, IDH1 mutation is 
associated with prolonged overall survival and therefore of prognostic value [17]. 
This is reflected within the recent WHO classification distinguishing GBM subtypes 
based on the mutational status of IDH. We now differentiate between three GBM 
subtypes: GBM with IDH wildtype (primary GBM), with mutated IDH (secondary 
GBM) and GBM not otherwise specified (NOS) [3]. 
The second routine molecular marker for GBM is the MGMT promoter methylation 
status [18]. The importance of MGMT derives from its function as a repair enzyme 
that reverses DNA cross-links at the O6 position of guanine [19] and, in a clinical 
context, thus opposes the effects of DNA alkylating substances, such as 
temozolomide (TMZ) and nitrosoureas. [16]. In 2000 the predictive value of MGMT 
gene silencing via hypermethylation for WHO grade III and IV entities was shown by 
Esteller et al. [20]. Patients with a methylated MGMT promotor phenotype 
responded significantly better to carmustine treatment (12 of 19 vs. 1 of 28) and 
their median progression free survival was prolonged by 13 months. Later, Hegi et 
al. [21] published studies which revealed a positive correlation between MGMT gene 
silencing and temozolomide therapy. Therefore, the decision whether an adjuvant 
therapy with alkylating substances is beneficial for GBM patients is highly 
dependent on the MGMT promoter methylation status of the tumor (see further 
down).  
1.1.3  Therapy 
Today, treatment of GBM starts with navigated (ultrasound or MRI based guidance) 
microsurgical resection, aiming for gross total resection [18]. According to guidelines 
for glioma therapy, surgery using 5-aminolevulinic acid [22] should be the first 
choice for patients with newly diagnosed glioblastoma. Tumor exstirpation should 
then be followed by adjuvant radio-chemotherapy (RCx) [18]. Conformal radiation 
up to 60 Gy in 2 Gy fractions remains the standard for primary GBM treatment [23]. 
Depending on MGMT status and the patient’s general condition, X-irradiation is 
accompanied by treatment with temozolomide (TMZ), called concomitant RCx. 
Then, prolonged adjuvant therapy with TMZ can be applied. Whether prolonged 
chemotherapy with TMZ should extent 6 cycles is controversial and still under 
investigation [24]. TMZ was approved by the Food and Drug Administration, United 
States, [25] in reaction to a phase-III-study performed by Stupp et al. [26], 
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demonstrating significantly prolonged survival of patients combining radiotherapy 
with TMZ treatment. Tumor-treating fields, using alternating electric fields in order to 
inhibit mitosis through spindle apparatus disruption, showed promising results [27], 
yet remain controversial [28]. 
Treatment guidelines of recurring GBM are more unprecise and there is no 
standardized therapy regimen [28]. In general, treatment includes re-surgery, re-
irradiation, second-line monotherapy or combination chemotherapy [29].  
1.1.4 GBM cell migration and invasion 
As mentioned before, highly infiltrative behavior is a hallmark of GBM cell biology 
playing a crucial role for patients' prognosis  [3]. In fact, as demonstrated by Sahm 
et al., diffuse glioma cells can be found throughout the whole brain [30]. Hence, R0 
resection of GBM, or high-grade glioma in general, is virtually impossible and 
malignant gliomas should be treated as systemic brain diseases. 
Cancer cell infiltration depends on the cancer cell’s specific physiology as well as a 
complex interplay with extra-cellular matrix (ECM) and tumor cell microenvironment 
[31]. In the case of gliomas, ECM and tumor microenvironment include specific 
macroscopic brain structures as glioma cells follow white matter tracts and the 
perivascular space to diffusely infiltrate the whole brain, as already shown in 1940 
[32]. The following part will illustrate some characteristics how GBM cells interact 
with ECM and tumor microenvironment within the CNS.  
The first phenomenon specific to glioma cell migration and invasion is the so called 
‘go and grow’ theory. It has first been described by Giese et al., defining proliferation 
and migration as mutually exclusive events in high-grade astrocytoma cells in vitro 
[33]. Later, it has been assumed in bio-mathematical models that this dichotomy can 
not only be driven by mutational heterogeneity within GBM but must also be 
triggered by microenvironmental factors such as hypoxia [34], and there is indeed 
evidence for both. Several factors have been identified to either stimulate GBM cell 
proliferation by inhibiting migration and vice versa. This, for example, includes 
microRNA-451 [35] or EbBH 2 receptor [36], but also better-known targets such as 
vascular endothelial growth factor (VEGF) [37]. Additionally, GBM cells within the 
tumor mass or the tumor rim, respectively, show different overexpression patterns 
for transcriptional factors such as c-myc or NF-κB, which are either involved in GBM 
cell migration (NF-κB, cells of the tumor rim) or proliferation (c-Myc, cells of tumor 
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center) [38]. Moreover, a work published in 2016 proofed that the regulation of the 
pentose phosphate pathway and glycolysis in glioblastoma cells by oxygen levels of 
the tumor environment strongly influence whether a cell migrates or proliferates [39]. 
The second principle which is used by GBM cells to disseminate is chemotaxis. It 
defines the mechanism when the direction of cell movement is driven by an 
extracellular chemo gradient [40]. Here, bradykinin and oxygen play important roles 
for perivascular infiltration of glioma cells. It is a common fact that bradykinin is 
produced by vascular endothelium through enzymatic cleavage to regulate vascular 
permeability. In a series of experiments, it has been demonstrated by Montana and 
Sontheimer that glioma cells express bradykinin 2 receptors which allow them to 
follow a chemo-gradient towards the bradykinin-rich perivascular space in the brain 
[41]. GBM is also characterized by central necrosis caused by oxygen deprivation, 
resulting in a constant urge to move towards the more oxygen-rich perivascular 
space [42]. Here, hypoxia-induced factor 1 (HIF-1) plays a pivotal role and has been 
shown to regulate pathways involved in cell migration and infiltration, such as 
production of matrix-metalloproteases, ECM remodeling and angiogenesis via 
VEGF secretion [43].  
Although ECM only comprises approximately 20% of brain parenchyma, which 
renders the brain to be overall a rather soft organ [44], perivascular basement 
membranes composed of collagen IV, laminin, heparan sulphate proteoglycans and 
others [45] are rigid. Interestingly, a work published in 1999 by Mahesparan et al. 
[46] demonstrates that migration of GBM cells obtained from glioma biopsy 
specimen is induced by laminin, fibronectin, collagen type IV and vibronectin in vitro. 
This phenomenon has been termed mechanotaxis or durotaxis [47] and appears to 
be important for glioma cell migration and invasion following white matter tracts [48]. 
 
1.2 Carnosine 
The high malignancy of GBM, which is reflected by the low progression free and 
overall survival of patients, is an ongoing challenge, and new treatment strategies 
and new compounds are investigated by many research teams world-wide. In our 
group, we focus on the potential use of the naturally occurring dipeptide to evaluate 
whether its anti-neoplastic effect could be employed for the treatment of GBM 
patients. 
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1.2.1  Chemistry, Biology, Distribution 
The dipeptide β-alanyl-L-histidine, better known as L-carnosine, has been isolated 
for the first time in 1900 by Gulewitsch and Amiradzibi from Liebig's meat extract 
[49]. It is a member of the family of naturally occurring imidazole-containing 
dipeptides, which also includes homocarnosine (γ-Aminobutyryl-L-histidine) and 
carcinine (N-(2-(1H-Imidazol-5-yl)ethyl)-3-aminopropanamide; β-Alanylhistamine) as 
well as the naturally most common variants ophidine (β-alanyl-3-N-methyl-histidine) 
and anserine (β-alanyl-1-N-methyl-L-histidine) [50]. Histamine-containing dipeptides 
can be found throughout the vertebrate kingdom in kidney, brain and skeletal 
muscle [51]. Interestingly, anserine and ophidine cannot be found in human tissue 
[50]. Carnosine was detected in the olfactory system of various mammalian species 
and in a particular fraction of astrocytes known as Bergmann glia in the cerebellum 
of rodents [52]. In human tissues, highest concentrations of carnosine have been 
measured in skeletal muscle (21.3±4.2 mmol/kg dry mass in males) [53]. In 
comparison, the carnosine concentration of human brain tissue (3.0 µmol/100g) is 
considerably lower than that of homocarnosine (33.4µmol/100g) [54].  
1.2.2  Carnosine homeostasis  
Human carnosine homeostasis is well regulated by rather unspecialized enzymes. 
Carnosine synthetase (CS; EC 6.3.2.11), a member of the ATP-grasp family of 
ATPases, catalyzes the synthesis of carnosine from β-alanine and L-histidine and 
also catalyzes the formation of homocarnosine from L-histidine and γ-aminobutyrate 
with a 14 to 26-fold lower efficiency. Its activity is 98% cytosolic [55]. CS is related to 
ATP-grasp domain containing protein-1 that can be found in skeletal and heart 
muscle as well as in certain brain regions [56]. Within the CNS only 
oligodendrocytes contain the ability to form carnosine while carnosine uptake is 
restricted to astrocytes [57]. 
Carnosine degradation is catalyzed by two hydrolytic enzymes that are specific for 
carnosine and its related compounds. A carnosinase (CN) was first described in 
1949 and found in swine kidney [58]. Carnosinase 1 (CN1, EC 3.4.13.20), also 
called human serum carnosinase, exists extra-cellular and specifically degrades 
carnosine with a high activity and contains activity against homocarnosine. 
Interestingly, CN1 is undetectable in the blood of neonates and shows gradually 
increasing serum concentrations until the age of 13-15, whereas relatively higher 
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concentrations of CN1 can be found in human brain tissue [59, 60]. Carnosinase 2 
(CN2, EC 3.4.13.3), also called tissue carnosinase or cytosolic carnosinase, can be 
found in nearly every tissue of the human body. Having a broad spectrum of 
possible substrates in the presence of magnesium or cadmium, but not against 
homocarnosine, it should be referred to as non-specific cytosolic dipeptidase [60–
62]. Another difference to CN1 is that CN2 activity can be inhibited by bestatin [63]. 
Despite metabolic characteristics, reduced levels of CN1 protein have been found in 
GBM patients' serum [64] and a decreased CN1 activity was found in patients with 
systemic neurological diseases, such as Parkinson’s disease, epilepsy, motor 
neuron disease, multiple sclerosis, cerebrovascular incidents and dementia [65], 
[66]. Reduced CN1 plasma concentrations also seem to be linked to a bad 
prognosis in patients with malignancies, such as GBM or metastatic prostate cancer 
[67]. Overall, CN1 activity seems to be connected to levels of oxidative stress and 
cellular stress response which also lead to typical age-related brain changes [68].  
Generally, cellular cross-membrane uptake of carnosine in humans is realized 
through four transporters of the proton-coupled oligopeptide transporter family, 
namely: PEPT1, PEPT2, PHT1 and PHT2 [50]. PEPT1 can mainly be found on the 
luminal side of enterocytes, there being responsible for the absorption of peptides 
across the brush-border membrane [50, 69]. Its renal isoform, PEPT2, reabsorbs 
carnosine with a low capacity but high affinity from filtered urine back into the 
cytosol of epithelial cells [70]. Other studies indicate the crucial role of PEPT2 for 
carnosine homeostasis as it was found in the choroid plexus, astrocytes, human 
nasal epithelium and cardiomyocytes [71]. The physiological role of PHT1 and PHT2 
with regard to carnosine transport still remains unclear, as does their direction of 
transport. Evidence shows that these transporters can be found in skeleton muscle 
where they might be responsible for carnosine homeostasis (for further information 
see [50]). 
1.2.3  Physiological functions 
Many physiological properties are attributed to carnosine, which can be explained 
by its chemical and biochemical properties, such as its pH buffering capacity, its 
antioxidant effects and its metal chelating function. Therefore, tissues of most 
interest are muscle and CNS. Already in 1938 the pH buffering ability of carnosine 
was described [72, 73], proposing the idea that carnosine has a proton snatching 
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effect during the anaerobic glycolysis of contracting muscles. Because of its 
relatively high abundance in the olfactory bulb, where it is found in the same 
presynaptic vesicles as glutamate, it was also discussed whether carnosine may be 
involved in glutamatergic neurotransmission [74]. This idea is also supported by the 
fact that carnosine and other peptides appear to work as cell-specific glia-to-neuron 
neurotransmitters in the brain [75], and there is evidence that carnosine stimulates 
glutamate release of rat oligodendrocytes in vitro [76]. 
1.2.4 Therapeutic potential 
Since Holliday and McFarland demonstrated an anti-senescence and rejuvenating 
effect of carnosine [77, 78] and Shao et al. proved a reduction of telomere damage 
and shortening [79] (both in cultured human fibroblasts), carnosine is considered to 
have anti-aging effects [80]. A more recent work also showed carnosine’s effect on 
reducing oxidative stress and apoptosis in a galactose aging model of the brain [81]. 
Even in vivo carnosine demonstrated anti-aging effects, e.g. in Drosophila [82] or 
senescent-accelerated mice [83], showing a connection between a lifeform’s ability 
to respond to reactive oxygen species (ROS) and age. With regard to clinical 
investigations with patients, positive effects of carnosine have been assumed for 
autistic spectrum disorders [84], cataract and open-angle glaucoma [85], gulf war 
disease [86], schizophrenia [87, 88] or attention-deficit/hyperactivity disorder in 
children [89]. Another interesting aspect is carnosine’s involvement in glycemic 
control and therefore diabetes and its consequences. Nagai et. al demonstrated that 
blood glucose concentrations can be lowered by carnosine [90]. In addition, oral 
carnosine supplementation proved to prevent diabetic deterioration of liver and 
kidney in diabetic Balb/cA mice [91]. A first clinical trial published in 2016 [92] 
demonstrated an influence of carnosine on postprandial blood glucose and insulin 
levels in patients with impaired insulin tolerance. 
1.2.5  Carnosine and cancer 
A potential use of carnosine for the treatment of cancer was discovered by Nagi and 
Suda [93] demonstrating an anti-neoplastic effect of carnosine in vivo on ddY mice 
with implanted sarcoma-180 cells. Later on, Holliday and McFarland confirmed 
these findings in vitro and were even able to show that HeLa cells can be selectively 
eliminated in co-cultures with fibroblasts, using a medium supplemented with 20 mM 
carnosine [94]. Because these results could be inhibited by supplementing pyruvate 
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and because carnosine has previously been shown to react with aldehyde and keto 
groups of sugars by an Amadori reaction [95, 96], they suggested an inhibitory 
effect of carnosine on glycolysis. This idea also took into account that tumor cells 
are highly dependent on glycolysis – known as the Warburg effect [97], which could 
be proven true for many different tumor entities [98]. Until today, the anti-neoplastic 
effect of carnosine has been shown for various types of cancer, such as colorectal 
cancer [99–101], human gastric cancer cells [102] or human renal carcinoma cells 
[103]. In a series of experiments performed at the Department for Neurosurgery of 
the Medical Faculty at the University of Leipzig, this anti-tumor activity was 
investigated for malignant gliomas [104–106], demonstrating a reduced ATP 
production of T98G cells in vitro and a link between carnosine treatment and 
alterations in protein folding. Additionally, we recently were able to present the 
influence of carnosine on epigenetic regulation in GBM cells [107]. To get a deeper 
understanding of how carnosine might influence cell tumor signaling, some possible 
mechanisms will be discussed briefly (for a more detailed presentation see [108]). 
Due to its ability of buffering ROS, carnosine was shown to inhibit the activation of 
Extracellular-signal Regulated Kinases 1/2 (ERK1/2) in neurons [109]. An earlier 
investigation already demonstrated that carnosine strongly inhibits the 
phosphorylation of ERK 1/2, mitogen-activated protein kinase p38 (p38 MAPK) and 
Akt in Caco-2 cells, an intestinal epithelial cell line, thus inhibiting the 
phosphorylation of Eukaryotic translation initiation factor 4E (eIF4E) [110]. This 
indicates a possible effect of carnosine on the MAPK/ERK-pathway, which is 
involved in cell proliferation, migration, survival and angiogenesis [111]. Another 
possible mechanism by which carnosine might affect tumor cell growth could be 
downregulation of HIF’s (a detailed summary about HIF is given in [112]), as 
demonstrated by experiments with human colon cancer cells [100, 101].  
 
1.3  Objective of the study 
 
Due to its poor prognosis caused by high tumor cell proliferation, invasiveness and 
the localization within the central nervous system [3], the diagnosis of glioblastoma 
is always devastating news for patients and remains challenging for neurosurgeons, 
neurologists and (radio-)oncologists. Even an aggressive therapy regimen, 
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consisting of gross total resection and adjuvant chemo-radiotherapy, leads to a 
short overall survival of patients [5]. Therefore, the need for new therapeutic drugs is 
evident and the key point in glioblastoma research. One strategy could be the 
inhibition of glioblastoma cell proliferation and migration into healthy tissue. 
Interestingly, it has been discussed before that high cell proliferation and migration 
are mutually exclusive events in tumor cells, called the ‘go and grow’ principle [34]. 
Hence, a new cancer drug should not inhibit one while promoting the other. In the 
past, we already proved that carnosine reduces the viability and metabolic activity of 
glioblastoma cells [104–106]. This work aimed at investigating, whether carnosine, 
while reducing glioblastoma cell proliferation, is also impairing the ability of tumor 
cells to migrate and consecutively to invade into surrounding tissue. To do so, we 
compared the metabolic effects of carnosine on primary glioblastoma cells and 
fibroblasts and established a new co-culture model to evaluate the effect of 
carnosine on glioblastoma cell invasion.  
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Carnosine selectively inhibits 
migration of IDH-wildtype glioblastoma cells 
in a co-culture model with fibroblasts
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Wolf Müller3, Jürgen Meixensberger1 and Frank Gaunitz1* 
Abstract 
Background: Glioblastoma (GBM) is a tumor of the central nervous system. After surgical removal and standard 
therapy, recurrence of tumors is observed within 6–9 months because of the high migratory behavior and the infiltra-
tive growth of cells. Here, we investigated whether carnosine (β-alanine-l-histidine), which has an inhibitory effect on 
glioblastoma proliferation, may on the opposite promote invasion as proposed by the so-called “go-or-grow concept”.
Methods: Cell viability of nine patient derived primary (isocitrate dehydrogenase wildtype; IDH1R132H non mutant) 
glioblastoma cell cultures and of eleven patient derived fibroblast cultures was determined by measuring ATP in cell 
lysates and dehydrogenase activity after incubation with 0, 50 or 75 mM carnosine for 48 h. Using the glioblastoma 
cell line T98G, patient derived glioblastoma cells and fibroblasts, a co-culture model was developed using 12 well 
plates and cloning rings, placing glioblastoma cells inside and fibroblasts outside the ring. After cultivation in the 
presence of carnosine, the number of colonies and the size of the tumor cell occupied area were determined.
Results: In 48 h single cultures of fibroblasts and tumor cells, 50 and 75 mM carnosine reduced ATP in cell lysates 
and dehydrogenase activity when compared to the corresponding untreated control cells. Co-culture experiments 
revealed that after 4 week exposure to carnosine the number of T98G tumor cell colonies within the fibroblast layer 
and the area occupied by tumor cells was reduced with increasing concentrations of carnosine. Although primary 
cultured tumor cells did not form colonies in the absence of carnosine, they were eliminated from the co-culture by 
cell death and did not build colonies under the influence of carnosine, whereas fibroblasts survived and were healthy.
Conclusions: Our results demonstrate that the anti-proliferative effect of carnosine is not accompanied by an induc-
tion of cell migration. Instead, the dipeptide is able to prevent colony formation and selectively eliminates tumor cells 
in a co-culture with fibroblasts.
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Background
Isocitrate dehydrogenase (IDH)-wildtype glioblastoma 
is the most malignant brain tumor of the adult brain 
and designated as Grade IV tumor by the World Health 
Organization (WHO) [1]. All tumors used in this study 
were IDH1R132H-non-mutant glioblastoma of elderly 
patients and, for reasons of simplicity, will further be 
referred to as GBM. Aside from a high mitotic activity 
and its ability to vascularize, GBM, as all diffuse glioma, 
has a high potential to infiltrate into intact brain tis-
sue which makes it virtually impossible for the surgeon 
to completely remove the tumor. Cells able to migrate 
within intact tissue are considered to be the main cause 
of tumor recurrence which is generally observed within 
6–9 month after surgery and standard therapy [2]. There-
fore, any therapeutic approach has to consider that it 
may not be enough to inhibit the proliferation of cells, 
but should although prevent their spreading into intact 
tissue. Moreover, as Giese et  al. [3] pointed out already 
more than 20  years ago, proliferation and migration 
appear to be mutually exclusive behaviors. The con-
cept of a dichotomy of proliferation/migration has been 
observed by many groups and has coined the term “go 
or grow” [4]. Having this dichotomy in mind it is impor-
tant that a substance that inhibits proliferation does not 
at the same time trigger migration and invasive behavior. 
This is the case for the dipeptide l-carnosine (β-alanyl-
l-histidine). This naturally occurring dipeptide has been 
discovered in 1900 by Gulewitsch and Amiradzibi [5]. 
Aside from a number of physiological roles attributed 
to it, such as pH-buffering or the chelation of metal ions 
(for review see [6]), it is discussed as a potential drug for 
the treatment of tumors (for reviews see [7, 8]). After the 
first observations made by Nagai and Suda [9] and the 
rediscovery of its anti-neoplastic effect by Holliday and 
McFarland [10], carnosine’s anti-tumor effect has been 
shown in vitro for a variety of cells derived from different 
tumors. This, for instance, includes gastric cancer cells 
[11], colon cancer cells [12] and, with special emphasis 
to this work, cells derived from glioblastoma [13]. Unfor-
tunately, the exact mechanisms by which the dipeptide 
exerts its anti-neoplastic effect are still unknown but 
appear to be pleiotropic and dependent on the tumor 
cells investigated (for review see [14]).
Although previous experiments pointed towards the 
possibility that carnosine also reduces migration and 
infiltration via inhibition of Matrix Metalloproteinase-9 
in SK-Hep-1 hepatoma cells [15] and in oxygen–glucose 
deprived reactive rat astrocytes [16] tumor cell inva-
sion in these experiments was determined using trans 
well chamber assays, which cannot answer the question 
whether migration into tissue or a layer of cells will also 
be inhibited by the dipeptide. The same is the case with 
recently published experiments performed with HCT-
116 human colon cancer cells which also indicated that 
the invasion ability of these cells is significantly inhibited 
already at a concentration 0.5 mM carnosine [17]. There-
fore, we analyzed the infiltrative capacity of IDH-wildtype 
glioblastoma cells in the presence of carnosine in a newly 
developed co-culture model. In our model glioblastoma 
cells were seeded inside a cloning ring placed in the well 
of a 12 well plate, seeding patient-derived fibroblasts out-
side the cloning rings. The rings were removed after the 
cells had attached to the culture dishes and the cells were 
incubated for different periods of time in the absence and 
presence of different concentrations of carnosine. Finally, 
the infiltrative potential of the tumor cells was analyzed 
by determining the number of colonies formed within 
the fibroblast layer and the area they covered.
Materials and methods
Reagents
Unless stated otherwise, all chemicals were purchased 
from Sigma Aldrich (Taufkirchen, Germany). Carnosine 
was kindly provided by Flamma (Flamma s.p.a. Chignolo 
d’Isola, Italy).
Cell lines and primary cell cultures
The GBM cell line T98G, negative for IDH1R132H-muta-
tion and O-6-methylguanine-DNA methyltransferase 
(MGMT) promoter methylation, was obtained from the 
ATCC, genotyped using a PowerPlex 21 System (Pro-
mega; Mannheim; Germany) by the Genolytic GmbH 
(Leipzig, Germany) and authenticated by comparison to 
data at the ATCC and the DSMZ. T98G cells were used 
at passage 5–7 after genotyping and authentication. Both, 
primary GBM cultures and primary fibroblast cultures 
were established from tissue samples obtained during 
standard surgery performed at the Neurosurgery Depart-
ment of the University Hospital Leipzig during 2015 and 
2016. All patients provided written informed consent 
according to the German laws as confirmed by the local 
committee. When possible, one primary GBM cell cul-
ture and one primary fibroblast culture was established 
from tissue samples obtained from each patient (Addi-
tional file 1: Table S1). All GBM samples were diagnosed 
and have been approved by the Neuropathology Depart-
ment of the Leipzig University Hospital. IDH 1 status 
has been determined using immunohistochemistry and 
pyrosequencing, MGMT promoter methylation status 
was determined using nucleic acid amplification followed 
by pyrosequencing.
For cultivation, tissue specimens from the tumor, 
from galea or from periost were cut into approximately 
1  mm3 large pieces and then separately placed into 
25 mm2 culture flasks (TPP, Trasadingen, Switzerland) 
14
Page 3 of 10Oppermann et al. Cancer Cell Int  (2018) 18:111 
until tumor cells or fibroblasts grew out. When more 
than 90% confluence was reached specimens were 
removed and primary cell cultures were transferred 
into 75  mm2 culture flasks (TPP) for further cultiva-
tion. Cell cultures were maintained in high glucose 
DMEM (4.5  g glucose/ml) supplemented with 2  mM 
Glutamax™, 1% penicillin/streptomycin (all from 
Gibco Life Technologies, now Thermo Fisher Scien-
tific, Darmstadt, Germany) and 10% FBS (Biochrom 
GmbH, Berlin, Germany), further referred to as 
“standard medium”, and kept in incubators (37  °C, 5% 
 CO2/95% air).
Cell viability assays
For cell viability assays, cells were counted and seeded 
into sterile 96-well plates (µClear, Greiner Bio One, 
Frickenhausen, Germany) at a density of 5000 cells/well 
in 200  µl standard medium. After 24  h of cultivation 
(37 °C, 5%  CO2/95% air) the medium was aspirated and 
fresh medium supplemented with or without carnosine 
was added (100 µl/well) and the cells were incubated for 
additional 48  h. Then, the CellTiter-Glo Luminescent 
Cell Viability Assay (CTG, Promega, Mannheim, Ger-
many) was employed to determine viable cells by meas-
uring ATP in cell lysates and the CellTiter-Blue Cell 
Viability Assay (CTB, Promega) was used to quantify 
the cell’s metabolic capacity in living cells. All assays 
were carried out according to manufacturer’s protocols. 
Luminescence and fluorescence were measured using a 
SpectraMax M5 multilabel reader (Molecular Devices, 
Biberach, Germany).
Co‑cultivation of GBM cells and fibroblasts (ring‑cultures)
When cells reached more than 90% confluence in 
75  cm2 cell culture flasks they were detached using 
accutase (Thermo Fisher), counted and diluted for 
co-cultivation. The ring-cultures were established in 
12-well plates. Therefore, sterile cloning rings (steel, 
6  mm inner; 8  mm outer diameter, Hartenstein, Wür-
zburg, Germany) usually used for the isolation of 
clones, were placed in the middle of each well divid-
ing it into an inner-ring and an outer-ring part. Then, 
2500 tumor cells suspended in standard medium 
(112 µl) were seeded inside the ring. Afterwards, 50,000 
fibroblasts (in 658  µl standard medium) were seeded 
outside of the ring  (Additional file  2: Figure S1). Co-
cultures with cloning rings were incubated for 4  h 
(37 °C, 5%  CO2/95% air) before the rings were carefully 
removed using sterile forceps. Medium was exchanged 
immediately after ring removal containing various 
concentrations of carnosine. On the following days 
medium was exchanged twice a week.
Carnosine co‑culture experiments
Carnosine was diluted in 0.7% NaCl solution and car-
nosine experiments were performed with concentra-
tions of 0 mM, 10 mM, 25 mM, 50 mM and 75 mM. All 
ring-culture experiments were prepared as described 
above. Control experiments with T98G cells inside the 
ring and without fibroblasts in the outer part were kept 
for over 2 weeks. Ring co-cultures with T98G and fibro-
blasts (P0385) and with GBM cells and fibroblasts of the 
same patient (P0383 with P0385 and P0431 with P0433) 
were cultivated for 4 weeks. Throughout cultivation, cell 
growth and dissemination were monitored by bright field 
microscopy. After 4 weeks all co-cultures were fixated in 
4.5% paraformaldehyde and stored in 1% sodium azide 
solution at 4 °C until microscopic analysis.
Immunostaining
Immunofluorescent staining was carried out to discrimi-
nate between tumor cells and fibroblasts using anti-
fibroblast TE-7 (CBL271, Merck Millipore, Darmstadt, 
Germany), anti-nestin (AB5922, Merck Millipore) and 
secondary antibodies (ab6563, ab150081, abcam, Cam-
bridge, UK). Briefly, for the detection of TE-7 the fixated 
co-cultures were permeabilized with 0.1% TritonX-100 
at room temperature (RT) for 5 min. After blocking with 
10% goat serum for 15 min, samples were incubated 
with anti-fibroblast TE-7 primary antibodies (dilution 
1:100) at 5 °C overnight, washed with TBS (20 mM Tris, 
134 mM NaCl) and subsequently incubated with the sec-
ondary antibody (1:250; ab6563) for 45  min at RT. For 
the detection of nestin, fixated cell cultures were per-
meabilized with 0.1% TritonX-100 in TBS for 1 h at RT, 
blocked for 15 min with 10% goat serum and then incu-
bated with an anti-nestin antibody (dilution 1:250) for 1 h 
at RT. Afterwards, cultures were washed with TBS and 
incubated with a dilution of secondary antibody (1:250; 
ab150081) for 45  min at RT. Finally, nuclei were coun-
terstained with DAPI (4  µg/ml) and cell cultures were 
preserved in 10% sodium azide solution at 4  °C until 
microscopy.
Microscopy
For microscopic analysis a Zeiss Axiovert 200M micro-
scope (Zeiss, Oberkochen, Germany) equipped with a 
motorized stage (Märzhäuser, Wetzlar, Germany) with 
MosaiX software and by means of a CCD camera (Zeiss 
MRC) connected to an AxioVision 4.8.2 image analysis 
system (Zeiss) was used to create tile pictures. Each tile 
picture is composed of 285 single microscopic images 
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taken at a magnification of 50 and represents a whole 
well of a 12-well plate. As denoted in the figure legend to 
Fig. 2 ImageJ images in this figure have been graphically 
enhanced for representation purposes using the Corel 
Draw Graphics Suite 2017 (Corel Corporation, Ottawa, 
Canada).
Quantitative and statistical analysis
The number of colonies in ring co-culture experiments 
was determined using ImageJ after a color threshold and 
a common pixel size were defined. All pictures used for 
the analysis were taken at the same magnification and 
had the same size. Statistical analysis was performed 
using the algorithm for t-test implemented in Microsoft 
Excel 2010.
Results
Viability of patient derived fibroblasts and GBM cells 
under the influence of carnosine
In order to figure out how fibroblasts isolated from 
patients who underwent surgery for GBM do respond to 
the presence of carnosine, 11 primary fibroblast cultures 
derived from galea or periost were exposed to different 
concentrations of carnosine. Viability was determined by 
measuring the amount of ATP in cell lysates and by the 
analysis of metabolic activity, as reflected by dehydroge-
nase activity. In order to compare the effect of the dipep-
tide on fibroblasts, we performed the same experiment 
with 9 primary GBM cell cultures derived from patients 
and cells from the GBM cell line T98G. All cells were 
seeded at a density of 5000 cells into the wells of 96-well 
plates and exposed to carnosine for 48  h. The result of 
the experiment is presented in Fig. 1. At a concentration 
of 50 mM carnosine, the amounts of ATP and the meta-
bolic activity in fibroblasts were significantly reduced 
compared to untreated control cells (metabolic activity: 
89.4% ± 7.53, p < 0.005; ATP: 96.6% ± 5.08%. p < 0.05). 
We also observed a significant reduction of metabolic 
activity in primary GBM cells treated with 50  mM car-
nosine (compared to untreated control: 79.7% ± 18.51%, 
p < 0.05). However, although the amounts of ATP were 
decreased at 50  mM carnosine (87.8% ± 16.35% com-
pared to the untreated control) this effect was not sig-
nificant (p = 0.056). Increasing the concentration of 
carnosine to 75  mM leads to a significant reduction 
of metabolic activity and a decrease in the amounts of 
ATP in both, primary GBM cells (metabolic activity: 
61.2% ± 18.96, p < 0.0005; ATP: 71.5% ± 19.68%. p < 0.005) 
and fibroblasts (metabolic activity: 81.5% ± 12.03, 
p < 0.0005; ATP: 88.4% ± 5.07%. p < 0.005) compared to 
the untreated control. Furthermore, in the presence of 
75 mM carnosine, viability of primary GBM cells was sig-
nificantly stronger reduced than in fibroblasts (metabolic 
activity: p < 0.05; ATP: p < 0.05).
Please also note, that for statistical analysis data 
obtained from experiments with the cell line T98G were 
excluded.
Outgrowth of cells from a ring culture 
without co‑cultivated fibroblasts
Next, we asked how carnosine influences the growth of 
glioblastoma cells over a longer period of time when they 
start to grow after being seeded inside of a cloning ring 
and removal of it in the absence of other cells. There-
fore, 2500 cells from the glioblastoma cell line T98G 
were seeded inside a cloning ring placed in a 12-well 
plate. Four hours later the rings were removed and the 
cells were allowed to grow for 2  weeks in the absence 
and presence of carnosine (10 mM, 25 mM, 50 mM and 
75  mM). Medium was exchanged twice a week. After 
fixation of cells, 285 tiled images were taken from each 
well for each concentration employed (in quadruplicate) 
and the area covered by tumor cells was determined 
using ImageJ. The result of the experiment is presented 
in Fig. 2. As can be seen, the tumor cell covered area is 
continuously decreasing with increasing concentrations 
of carnosine although the effect becomes significant only 
at a concentration of 50 mM carnosine. At a concentra-
tion of 75  mM carnosine, no tumor cells were remain-
ing on the plates, demonstrating that this concentration 
Fig. 1 Viability of patient derived fibroblasts and primary 
glioblastoma cells under the influence of carnosine. Fibroblast 
cell cultures (11) and primary GBM cell cultures (9) were exposed 
for 48 h to different concentrations of carnosine (0, 50 or 75 mM). 
Viability was determined by measuring the amount of ATP in cell 
lysates (a) and by assessing metabolic activity (b). Each dot within 
the boxplots represents the mean obtained from six measurements 
of an individual cell culture. For comparison, the grey-colored dots 
(depicted by arrows) indicate the results obtained from experiments 
with the cell line T98G which was used for co-culture experiments. 
Statistical significance using data obtained from 11 fibroblast cultures 
and 9 primary GBM cultures was determined using Student’s t-test 
with: *p < 0.05; **p < 0.005; ***p < 0.0005
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does not only inhibit proliferation but also eliminates the 
tumor cells when exposed to the dipeptide for 2 weeks. 
In conclusion, the experiment demonstrates that the cells 
do survive for 2 weeks when seeded at a density of 2500 
cells inside a cloning ring and are incubated at carnosine 
concentrations of 50 mM or below.
Fluorescent discrimination of tumor cells and fibroblasts 
in co‑culture
In order to perform co-culture experiments with GBM 
cells and fibroblasts, we had to establish a method by 
which both types of cells can be discriminated. Using 
patient derived fibroblasts (P0385) and primary glio-
blastoma cells (P0383) we were able to discriminate both 
types of cells using an antibody directed against nestin 
(Fig.  3). Although both types of cells were detected by 
the anti-nestin specific antibody, staining was signifi-
cantly more intense on GBM cells allowing discrimina-
tion between both types of cells as demonstrated by the 
images presented in Fig. 3.
Unfortunately, discrimination between fibroblasts and 
cells from the glioblastoma cell line T98G was not pos-
sible using the nestin-specific antibody. We found a solu-
tion, using an anti-body directed against TE-7 which 
stains an unknown antigen specific for fibroblasts [18]. 
As demonstrated in Fig.  4 the TE-7 specific anti-body 
did also stain the nuclei of T98G cells, but did not detect 
antigen in their cytoplasm. Therefore, counterstaining 
with DAPI (color-coded in red) and TE-7 (color-coded in 
green) results in a yellow color of T98G nuclei and fibro-
blasts appear in green (cytosol) with red nuclei. At this 
point it should also be noted that the TE-7 specific anti-
body did also stain cells in primary GBM cultures which 
is the reason why this antibody had not been used for co-
cultures with primary cells.
Colony formation of T98G tumor cells in ring culture 
with fibroblasts under the influence of carnosine
Next we asked whether T98G cells seeded inside a 
cloning ring can migrate into a surrounding layer of 
Fig. 2 Outgrowth of T98G cells under the influence of carnosine. 
T98G cells were seeded inside a cloning ring placed in a 12-well 
plate. Rings were removed after 4 h and cells were allowed to 
grow in the presence of 0, 10, 25, 50 and 75 mM carnosine. After 
14 days, images were taken and the area covered by tumor cells was 
determined. The mean and standard deviation of the covered area 
from four independent wells for each concentration are presented 
in a. A statistical significant reduction was only seen at 50 mM 
carnosine (*) and at a concentration of 75 mM carnosine no tumor 
cells were left on the plates. In the lower part of the panel examples 
of images are presented that were used for data analysis (b without 
carnosine; c 10 mM; d 25 mM and e 50 mM carnosine). #2 presents 
the corresponding ImageJ processed pictures (Note: for presentation 
purposes the pictures shown have been vectorized and image 
enhanced using Corel Draw Graphic Suite 2017)
Fig. 3 Nestin staining of patient derived GBM cells and fibroblasts in ring co-culture. The figure shows staining of a co-culture of fibroblasts (P0385) 
with GBM cells (P0383) with DAPI (a), a nestin-specific antibody (b) and the merged image (c). GBM cells are presented in bright green at the right 
side of the image. Scale bar: 300 µm
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fibroblasts and whether migration and development of 
tumor cell colonies inside the fibroblast layer is influ-
enced by carnosine. Therefore, ring co-cultures were 
established with T98G cells inside the cloning ring and 
fibroblasts (P0375) outside of it. After removal of the 
ring, cells first have to migrate towards each other filling 
the gap left after ring removal. As presented in Fig. 5 cells 
are migrating to fill the gap within 4–11 days. As can be 
seen, both, fibroblasts (right side) and T98G cells are able 
to migrate towards each other, filling the gap between 
day 4 and day 11 in the absence of carnosine. In the pres-
ence of 50 mM carnosine migration is impaired in both 
types of cells as shown in the image taken after 4  days. 
At day 11 the gap gets filled, too, but it seems that mainly 
fibroblasts are located in the previous gap (Note: This 
experiment resembles a classical scratch assay). In a fol-
lowing series of experiments ring co-cultures of T98G 
cells and fibroblasts (P0375) incubated for 4 weeks in dif-
ferent concentrations of carnosine (0, 10, 25 and 50 mM) 
were fixated and stained with DAPI and the TE-7 specific 
antibody. After fluorescence microscopy the number of 
colonies formed by T98G cells and the area occupied by 
tumor cells was analyses using ImageJ. In Fig. 6a example 
fluorescence images of cultures and their corresponding 
ImageJ derived images are presented as well as the result 
of the determination of area occupancy (Fig. 6b) and the 
measurement of the number of colonies formed (Fig. 6c). 
As can be seen, the size of the area occupied by tumor 
cells and the number of colonies are decreasing with 
increasing concentrations of carnosine. In the absence 
of carnosine tumor cells occupied 13.5% ± 3.5% of the 
plate. Already in the presence of 10 mM carnosine area 
occupancy was significantly decreased to 7.7% ± 2.5% 
(p < 0.05) and diminished further by increasing con-
centrations of carnosine (25  mM: 6.0% ± 3.0%, p < 0.05; 
50  mM: 3.1% ± 3.3%, p < 0.0005). In addition, the num-
ber of colonies decreased with increasing concentrations 
from 80.8 ± 46.8 colonies in the absence of carnosine to 
46.6 ± 24.4 colonies (10 mM; not significant), 28.8 ± 24.0 
(25  mM, p < 0.05) and to 1.5 ± 0.8 colonies (50  mM, 
p < 0.05). This clearly demonstrates that carnosine inhib-
its the potential of T98G cells to infiltrate the fibroblast 
layer.
Fig. 4 TE-7 staining of T98G cells and fibroblasts in mono-, co- and in ring co-culture. The figure shows staining in mono cultures of fibroblasts 
(P0375) with DAPI (a), with a TE-7-specific antibody (e) and the merged image (i) and the corresponding images of staining of T98G cells (b, f, j). 
Images c, g and k were taken from a co-culture of both cells and d, h and f shows an image of a ring culture at low magnification. Fibroblasts 
appear with green staining in the cytoplasm and red nuclei, whereas T98G cells are presented by their yellow stained nuclei in the merged images. 
Scale bars a–c, e–g, i–k 30 µm, d, h, i 120 µm
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Fig. 5 Cells migrating into the gap after removal of the cloning ring in a co-culture of T98G cells and fibroblasts. T98G cells (2500) were placed 
inside the cloning ring and fibroblasts (P0375; 50.000) outside of it. Migration of cells into the gap left after removal of the cloning ring 3, 4 and 
11 days after ring removal with fibroblasts on the right side and T98G cells to the left as detected by bright field microscopy is presented. In the 
upper panel cultures were incubated in medium without carnosine and in the lower panel in medium containing 50 mM carnosine. Scale bar: 
30 µm
Fig. 6 Colony formation of T98G cells in a fibroblast layer in the presence of different concentrations of carnosine. T98G cells (2500) were placed 
inside the cloning ring and fibroblasts (P0375; 50.000) outside of it. The ring was removed 4 h later and after 4 weeks of cultivation in the presence 
of different concentrations of carnosine the cultures were fixated and stained with DAPI and a TE-7 specific antibody. Fluorescence images are 
presented in the upper part of panel a and pictures generated by ImageJ for the determination of area occupancy and the number of colonies 
formed is presented in the lower part. On the right side of the graph, area occupancy (b 100% equals the whole well area) and the number of 
tumor cell colonies formed (c) is presented. Statistical significance using data obtained from 8 to 10 independently treated cultures for each 
concentration of carnosine was determined using Student’s t-test with: *p < 0.05; ***p < 0.0005
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Colony formation of primary glioblastoma cells in ring 
culture with fibroblasts under the influence of carnosine
In order to verify that the effect of carnosine is not 
restricted to a cell line but can also be seen with tumor 
cells derived from a patient, we also performed ring co-
culture experiments with two patient-derived tumor 
cell cultures (P0383 and P0431) and fibroblasts from the 
same patient (P0385 and P0433, respectively). Again, 
tumor cells were seeded inside the cloning ring and 
fibroblasts outside of it. After 4  weeks of cultivation 
cells were stained with DAPI and a nestin-specific anti-
body and analyzed using ImageJ. Surprisingly, we did 
not detect colony formation inside the fibroblast layer 
even in the absence of carnosine. On the other hand, the 
tumor occupied area was significantly reduced already 
at a concentration of 10 mM carnosine. As the two pri-
mary cultured glioblastoma cells occupied different areas 
in the absence of carnosine, we set the area occupied in 
the absence of carnosine for each cell culture as 100% in 
order to compare the effect of carnosine and to deter-
mine an average. We found a reduction of the occupied 
area to 68.1% ± 11.3% (p < 0.05) at a concentration of 
10 mM carnosine, to 70.6% ± 3.1% (p < 0.0005) at 25 mM 
and to 18.7% ± 3.0% (p < 0.0005) at 50 mM. Comparable 
to the experiments with T98G cells and fibroblasts pre-
sented in Fig. 6, the space previously occupied by tumor 
cells becomes occupied by the fibroblasts. (For compari-
son: setting the occupied area to 100% in the experiment 
with T98G cells the reduction is 57.0% ± 18.5% at 10 mM, 
44.4% ± 22.2% at 25  mM and 23.0% ± 24.4% at 50  mM 
carnosine).
Discussion
As outlined in the introduction, we and others have 
shown that the naturally occurring dipeptide carnosine 
inhibits the growth of cancer cells in  vitro and in  vivo 
[14], whereas beneficial effects have been observed in 
cultured human fibroblasts [19]. Using a colorimetric 
assay (tetrazolium compound [3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium, inner salt; MTS]) and human dermal 
fibroblasts, Ansurudeen et al. also demonstrated a greater 
number of viable cells in the presence of 50 mM carno-
sine after 24  h incubation [20]. Unfortunately, it is not 
traceable whether the fibroblasts used by Ansurudeen 
et  al. were from juvenile foreskin or from adult skin. In 
addition, the experiments performed by Holliday and 
McFarland were done by using a fibroblast cell line estab-
lished from human foreskin of a newborn male (HFF-1) 
and a second cell line established from lung tissue of a 
male at 14 weeks gestation (MRC-5). Considering using 
carnosine for the treatment of elderly patients the ques-
tion had to be answered whether fibroblasts isolated 
from adults or even senescent patients may behave differ-
ent to fibroblasts isolated from fetal or newborn human 
tissue. In our experiments presented in Fig. 1 we did not 
see a measurable beneficial effect of carnosine on fibro-
blast viability, although it is interesting to note, that 
fibroblasts cultivated in 50  mM carnosine appeared to 
be rejuvenated compared to fibroblasts cultivated in the 
absence of carnosine in accordance to the observations 
of McFarland and Holiday [21]. We also did not see any 
correlation between age of the patient, the tissue of ori-
gin or gender, though it has to be realized that the num-
ber of samples may be too low for such an analysis and 
most of our patients have been of comparable age. More 
importantly, a prolonged cultivation of fibroblasts as in 
the co-culture experiments demonstrates that the fibro-
blasts are alive and able to occupy the space left by dying 
glioblastoma cells even under the highest concentration 
of carnosine employed (50 mM). It is also very interest-
ing to note that we observed complete cell death of T98G 
tumor cells in long term culture incubating the cells at 
a concentration of 75  mM carnosine (Fig.  2). In previ-
ous experiments, cells were usually kept in the presence 
of carnosine for 24, 48 or 96 h [13] but not for 2 weeks. 
This is interesting, as shorter exposure times in previous 
experiments resulted in reduced proliferation but not 
complete elimination of tumor cells. Which processes 
are responsible for reduced tumor cell proliferation are 
under the influence of carnosine are still unknown [14]. 
However, it is an interesting question whether the pro-
cesses which reduce proliferation after short term expo-
sure may finally lead to cell death when the tumor cells 
are exposed to carnosine for a longer period of time.
In order to discriminate tumor cells from fibroblasts in 
ring co-culture experiments several markers were tested 
including glial fibrillary acidic protein (GFAP) which did 
also stained fibroblasts in accordance with observations 
made by others [22]. We finally identified that nestin-
staining was suitable to discriminate primary cultured 
tumor cells from patient-derived fibroblasts. Nestin is a 
class VI intermediate filament protein and a marker for 
neural stem cells. In addition, it has been reported as a 
cancer stem cell-specific marker [23] and a recent meta-
analysis performed by Lv et  al. [24] demonstrated that 
increased expression of nestin is positively associated 
with higher histological grade in glioma patients. This 
analysis also indicated that patients with higher nes-
tin expression are prone to recurrence and glioma cell 
infiltration into intact brain tissue. Surprisingly, in our 
ring co-culture experiments T98G cells, which did not 
express nestin, as previously reported by other investiga-
tors [25, 26], gave rise to many colonies in the surround-
ing fibroblast layer which was not the case when primary 
cultures with a high expression of nestin were cultivated 
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with fibroblasts. Although speculative, one interpretation 
could be that the primary cultures we used were of very 
early passages (Passage 1 and 5) and not as rapidly grow-
ing as T98G cells which is also reflected by their higher 
resistance towards carnosine (Fig. 1) as carnosine exerts 
its action mainly on metabolic highly active tumor cells 
[27]. Nonetheless, the results presented in Fig.  6 clearly 
demonstrate that colony formation is significantly inhib-
ited when invasively grown glioblastoma cells are treated 
with carnosine. In the last years, a so-called “go or grow 
concept” has been discussed, assuming that prolifera-
tion and migration are mutually exclusive phenomena 
in cancer cells [4]. Studies confirming this hypothesis 
are for example observations made in breast cancer cell 
lines in which overexpression of Homeobox Protein C9 
(HOXC9) resulted in increased invasiveness but at the 
same time inhibited proliferation [28]. Another exam-
ple is the observation that enforced expression of Y-box 
binding protein-1 (YB-1) in non-invasive breast epithe-
lial cells induces an epithelial–mesenchymal transition 
(EMT) resulting in an enhanced metastatic potential 
but at the same time reduces proliferation [29]. Unfortu-
nately, the exact mechanisms and down-stream targets 
responsible for either proliferation or invasion mediated 
by HOXC9 or YB-1 signaling are still unknown. More 
importantly, our results demonstrate that carnosine does 
not inversely influence proliferation and invasion. Up to 
now, the mechanisms responsible for the dipeptides anti-
proliferative effect, which has been confirmed in several 
studies with different types of cancer cells [11–13, 30] 
are still not understood. With regard to carnosine’s effect 
on migration and invasion it has been discussed that it 
involves regulation of matrix metalloproteinases (MMPs) 
[15], but more experiments are certainly needed to prop-
erly address this question.
Conclusions
This study demonstrates that carnosine’s anti-prolifer-
ative effect is not accompanied by increased invasion as 
suggested by the so-called “go-or-grow” concept. In fact, 
the dipeptide can inhibit tumor cell migration, which is 
especially important for the treatment of highly infiltrat-
ing and metastasizing tumors such as IDH-wildtype glio-
blastoma. In addition, the co-culture model presented is 
a valuable alternative to the commonly used scratch or 
Boyden chamber assays.
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Carnosine, ß-alanyl-L-histidine, is a naturally occurring dipeptide with the highest 
concentration in skeletal muscle and was discovered over 100 years ago [49, 53]. 
Research concerning carnosine mainly focuses on metabolic effects in muscle 
tissue [113–116] and the scavenging effect for reactive oxygen species [68], which 
seems to be highly related to anti-aging [83, 84] and responsible for its positive 
effects on neuro-degenerative diseases [65, 66, 68]. Additionally, in 1986 Nagai and 
Suda [93] demonstrated an anti-neoplastic effect of carnosine in a Sarcoma 180 
mouse model, which was later re-discovered by Holliday and McFarland on HeLa 
cells in vitro [94]. In the following course, Renner et al. were able to demonstrate an 
anti-neoplastic effect in glioblastoma (GBM) cells and gave rise to research 
concerning the effect of carnosine on glioblastoma (GBM) [104–106]. GBM is the 
most common malignant brain-derived tumor and associated with very poor 
prognosis [5]. It is characterized by central necrosis, high vascularization, highly 
infiltrative behavior and therefore classified as WHO grade IV tumor [3]. Diagnosis, 
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prognosis and treatment of GBM are highly dependent on the mutational status of 
isocitrate-dehydrogenase (IDH) and methylation of the promoter of O-6-
methylguanine-DNA methyltransferase (MGMT) [16, 17, 21]. This work focused on 
IDH-wildtype GBM, also called primary GBM. The median age of diagnosis for 
primary GBM is 64 years and common onset-symptoms are seizures, headache or, 
depending on its location, neurological deficits like paralysis or aphasia [3, 5]. 
Standard therapy for primary glioblastoma consists of microsurgery, aiming for 
gross total resection, and adjuvant radio-chemotherapy. Depending on the tumor’s 
MGMT promoter methylation status and the patients’ general condition (e.g. 
karnofsky performance score), chemotherapy with temozolomide is applied 
concomitantly to radiotherapy for patients with a methylated MGMT promoter and 
therefore of high prognostic relevance [18]. Since the discovery of temozolomide for 
GBM therapy in 2005 [26], no other systemic or local therapy has accomplished to 
be integrated as standard care into guidelines for GBM [28]. The two biggest 
challenges in glioblastoma therapy are its highly infiltrative behavior into adjacent 
brain tissue, which makes it virtually impossible to achieve a total resection, and its 
highly proliferative profile. Interestingly, the so called ‘go and grow’ principle 
assumes that a highly proliferative profile and high tumor cell migration are mutually 
exclusive events [34]. Thus, a new drug should address both issues in order to 
prevent the promotion of one by inhibiting the other. This work aimed at finding out, 
whether carnosine inhibits proliferation or infiltration or both characteristics of GBM 
to evaluate if carnosine might be a useful drug for the fight against glioblastoma.  
Primary cell cultures of fibroblasts and GBM cells were established from tissue 
samples obtained during neurosurgery performed at the University Hospital Leipzig 
between 2015 and 2016. The GBM cell line T98G was obtained from ATCC. In a 
first series of experiments, fibroblasts and GBM cells were separately seeded into 
96-well plates and treated with (10 mM, 25 mM, 50 mM, 75 mM) or without 
carnosine. After 48 hours, cell-based assays were performed to quantify ATP in cell 
lysates and dehydrogenase activity in living cells to measure the metabolic activity 
of primary fibroblasts and GBM cells under the influence of carnosine. The results 
show that carnosine significantly impairs the metabolic activity of both, fibroblasts as 
well as GBM cells. At a concentration of 75 mM the viability in glioblastoma cells 
was significantly reduced when compared to fibroblasts, demonstrating a more 
pronounced effect of carnosine on tumor cells than on fibroblasts.  
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To evaluate whether carnosine also inhibits migration and proliferation of GBM cells, 
ring-culture experiments were performed. Therefore, sterile cloning rings were 
placed in the middle of 12-well plate wells, dividing them into inner and outer ring 
parts. In a first step T98G cells were seeded into the inner ring part and rings were 
removed after 4 hours. Cells were then allowed to grow over the course of 2 weeks 
with (10 mM, 25 mM, 50 mM and 75 mM) or without the influence of carnosine. The 
outgrowth of T98G cells was visualized by microscopy and the area occupied by 
T98G cells was analyzed with ImageJ. The experiment revealed that already the 
lowest carnosine concentration of 10 mM inhibits tumor cell migration and 
proliferation, with significant effects at 50 mM carnosine. Furthermore, when 
incubated in the presence of 75 mM carnosine, no viable tumor cells remained on 
the plates showing that carnosine not only inhibits tumor cell growth but also 
eliminates them. We then asked, whether carnosine also reduces the ability of GBM 
cells to infiltrate a fibroblast layer as a model for surrounding tissue. In order to 
discriminate between fibroblasts and GBM cells we firstly established a staining 
protocol for our co-cultures using anti-nestin and anti-TE-7 antibodies. Ring cultures 
were then used to establish co-cultures of GBM cells and fibroblasts by seeding 
T98G or primary GBM cells within the cloning ring and fibroblasts outside of it. Co-
cultures were kept with (10 mM, 25 mM, 50 mM and 75 mM) or without carnosine 
over 4 weeks and the results were monitored using brightfield and fluorescence 
microscopy. Brightfield microscopy showed that carnosine reduces the migration 
rate of fibroblasts and T98G cells towards each other (into the space left after 
removing the ring) during the first days of monitoring, imitating a scratch assay. After 
4 weeks, fluorescence microscopy and ImageJ were used to analyze the area 
occupied by tumor cells and to count new satellite lesions of T98G cells within the 
fibroblast monolayer as markers for tumor cell infiltration. The results revealed that 
all concentrations of carnosine significantly reduced the area occupied by T98G 
cells and that concentrations above 10 mM also significantly decreased the number 
of newly formed tumor cell colonies within the fibroblast monolayer. To verify these 
results, the co-culture experiments were repeated using primary GBM cells and 
fibroblasts. Despite that no colony formation was seen using primary GBM cells, 
carnosine again reduced the area occupied by GBM cells significantly at all 
concentrations compared to untreated control cultures.  
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In summary, our work demonstrates that carnosine not only reduces the metabolic 
activity of glioblastoma cells compared to fibroblasts, but also impairs the ability of 
GBM cells to proliferate, migrate and infiltrate surrounding tissue in vitro. Moreover, 
the reduction of malignant cell growth under carnosine is independent from the „go 
and grow“ principle. Future experiments should now be performed to understand the 
molecular mechanisms responsible for carnosine’s effect on proliferation and 
migration and whether its effect on migration can also be observed under standard 
therapy conditions including temozolomide and X-irradiation. 
The work presented has been published in Cancer Cell International, 13 August 
2018 (PMID: 30123089).  
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5 Appendix 
 
5.1  Supplemental material 
 
Additional File 1: Patients and patient derived cell cultures. 
 
patient  cell type Label sex and 
age 
MGMT status 
GBM 
IDH status 
GBM 
1 Fibr. (P) P0375 m, 66 - - 
2 GBM P0383 f, 76 mildly positive negative 
Fibr. (P) P0384 
Fibr. (G) P0385 
3 Fibr. (G) P0408 f, 41 positive negative 
GBM P0410 
4 Fibr. (P) P0425 f, 67 mildly positive negative 
GBM P0424 
5 GBM P0411 m, 68 positive negative 
Fibr. (P) P0412 
6 GBM P0431 m, 66 positive negative 
Fibr. (G) P0433 
7 GBM P0441 f, 59 negative negative 
Fibr. (G) P0443 
8 GBM P0446 m, 65 positive negative 
Fibr. (G) P0447 
9 GBM P0451 f, 74 positive negative 
Fibr. (G) P0452 
10 GBM P0454 m, 70 negative negative 
Fibr. (G) P0455 
 
Primary cultures of glioblastoma cells (GBM) and fibroblast cultures either isolated 
from periost (Fibr. (P)) or from galea (Fibr. (G)) are shown together with patients’ 
age and sex and the status of promoter methylation of MGMT and whether the 
tumors are positive or negative for IDH mutation R132H as determined by 
pathology.  
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Additional File 2: Setup of ring-cultures. 
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